Neurocritical Care

, Volume 7, Issue 2, pp 140–147 | Cite as

Levetiracetam use in critically ill patients

  • Jerzy P. SzaflarskiEmail author
  • Jason M. Meckler
  • Magdalena Szaflarski
  • Lori A. Shutter
  • Michael D. Privitera
  • Stephen L. Yates
Original Paper



Levetiracetam (LEV) is used in the setting of acute brain injury for seizure treatment or prophylaxis but its safety and efficacy in this setting is unknown.


We retrospectively analyzed the patterns of use and safety/efficacy of LEV in 379 patients treated in the neuroscience intensive care unit (NSICU). We extracted from the charts clinical data including diagnosis, AED therapy before and during stay in the NSICU, complications of treatment, length of stay, and clinical outcomes (improvement, Glasgow Coma Scale, and death). We analyzed the data using binary and ordered (multi-category) logistic regression.


Overall, our findings are that phenytoin used prior to the NSICU admission was frequently replaced with LEV monotherapy (P < 0.001). Patients treated with LEV monotherapy when compared to other AEDs had lower complication rates and shorter NSICU stays. Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P ≤ 0.014).


The results of this study suggest that LEV is a frequently used AED in the setting of acute brain injury and that it may be a desirable alternative to phenytoin. Prospective studies evaluating the long-term safety, efficacy and outcomes of LEV in this setting are indicated.


Levetiracetam (LEV) Stroke Hemorrhage Tumor ICU Outcome Epilepsy 



Support for this study was provided by UCB, Inc. (UCB Young Investigator Research Project to Dr. Meckler); this work was presented in part at the American Epilepsy Society Annual Meeting in Washington, DC, 12/2005 and at the 7th European Congress of Epileptology, Helsinki, Finland, 7/2006. Drs. J.P. Szaflarski, Meckler, Shutter and Privitera received compensation for various activities sponsored by UCB Pharma. Dr. Yates is an employee of UCB, Inc.


  1. 1.
    LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA 2004;291(5):615–20.PubMedCrossRefGoogle Scholar
  2. 2.
    LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291(5):605–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41(9):1179–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55(2):236–42.PubMedGoogle Scholar
  5. 5.
    Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9(2):80–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41(10):1276–83.PubMedGoogle Scholar
  7. 7.
    van Breemen MS, Vecht CJ. Optimal seizure management in brain tumor patients. Curr Neurol Neurosci Rep 2005;5(3):207–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005;54(1):34–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN. The use of levetiracetam in refractory status epilepticus. Seizure 2006;15(3):137–141.Google Scholar
  10. 10.
    Wagner GL, Wilms EB, Van Donselaar CA, Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003;12(8):585–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284(2):474–9.PubMedGoogle Scholar
  12. 12.
    Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10(4):287–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991;265(10):1271–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36(3):583–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85(2):77–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Truog RD, Brock DW, Cook DJ, et al. Rationing in the intensive care unit. Crit Care Med 2006;34(4):958–63; quiz 71.Google Scholar
  17. 17.
    Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003;4(6):702–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68(6):402–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64(11):1868–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107(3):165–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27(3):195–204.PubMedCrossRefGoogle Scholar
  22. 22.
    Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26(3):451–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3(1):70–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27(3):205–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Leppik IE. Epilepsy in the elderly. Rev Neurol Dis 2004;1(Suppl 1):S44–55.PubMedGoogle Scholar
  26. 26.
    Ficker D, Meckler J, Szaflarski J, Shutter L, Warnick R. Use of Levetiracetam as pre-operative prophylaxis in brain tumour surgery patients. In: 26th International Epilepsy Congress; 2005; Paris, France: Epilepsia; 2005. p. Suppl.6:106.Google Scholar
  27. 27.
    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286(5439):487–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338(8):499–505.PubMedCrossRefGoogle Scholar
  29. 29.
    Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356(9226):285–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Khan RB, Hunt DL, Thompson SJ. Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004;19(2):97–101.PubMedGoogle Scholar
  31. 31.
    Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians’ recommendations for cardiac catheterization. N Engl J Med 1999;340(8):618–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 2003;93(12):2067–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Specchio LM, Boero G, Specchio N, et al. Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. Seizure 2006;15(2):112–6.PubMedCrossRefGoogle Scholar
  34. 34.
    French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005;46(2):324–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003;4(5):537–47.PubMedCrossRefGoogle Scholar
  36. 36.
    White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003;61(9):1218–21.PubMedGoogle Scholar
  37. 37.
    Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4(2):124–32.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Jerzy P. Szaflarski
    • 1
    • 2
    • 3
    Email author
  • Jason M. Meckler
    • 1
  • Magdalena Szaflarski
    • 5
    • 6
  • Lori A. Shutter
    • 1
    • 3
    • 4
  • Michael D. Privitera
    • 1
    • 2
    • 3
  • Stephen L. Yates
    • 7
  1. 1.Department of NeurologyUniversity of Cincinnati Medical CenterCincinnatiUSA
  2. 2.Cincinnati Epilepsy CenterUniversity of Cincinnati Medical CenterCincinnatiUSA
  3. 3.The Neuroscience InstituteUniversity of Cincinnati Medical CenterCincinnatiUSA
  4. 4.Department of NeurosurgeryUniversity of Cincinnati Medical CenterCincinnatiUSA
  5. 5.Institute for the Study of HealthUniversity of Cincinnati Medical CenterCincinnatiUSA
  6. 6.Department of Family MedicineUniversity of Cincinnati Medical CenterCincinnatiUSA
  7. 7.UCB, Inc. Medical AffairsSmyrnaUSA

Personalised recommendations